High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Trial ID or NCT#

NCT00003641

Status

not recruiting iconNOT RECRUITING

Purpose

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically. PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.

Official Title

Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Neyssa Marina
Harlan A Pinto
Harlan A Pinto
Medical oncologist, Head and neck specialist
Associate Professor of Medicine (Oncology), Emeritus

Contact us to find out if this trial is right for you.

Contact

CCTO
650-498-7061

View on ClinicalTrials.gov